Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.
Akihiro YamadaJingzhou WangYuga KomakiFukiko KomakiDejan MicicAtsushi SakurabaPublished in: Alimentary pharmacology & therapeutics (2019)
New onset IBD with the use of anti-IL-17 agents was rare. Interpretation of the results needs caution due to the presence of many zero-event studies.
Keyphrases